PHP
CGEM icon

Parkman Healthcare Partners’s Cullinan Oncology CGEM Stock Holding History

Parkman Healthcare Partners’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-178,396
Closed -$3.04M – 93
2024
Q1 		$3.04M Sell
178,396
-351,481
-66% -$5.43M 0.37% 72
2023
Q4 		$5.4M Buy
529,877
+91,132
+21% +$807K 0.76% 40
2023
Q3 		$3.97M Buy
438,745
+91,964
+27% +$958K 0.73% 39
2023
Q2 		$3.73M Buy
346,781
+176,895
+104% +$1.88M 0.65% 50
2023
Q1 		$1.74M Buy
169,886
+38,508
+29% +$425K 0.38% 60
2022
Q4 		$1.39M Buy
+131,378
New +$1.6M 0.37% 65

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's CGEM Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Cullinan Oncology (CGEM) in Q2 2024, closing a stake of 178,396 shares — an estimated $3.04M sold.

Parkman Healthcare Partners first reported a position in CGEM in Q4 2022 and held it in 6 quarters. The position peaked at $5.4M in Q4 2023. 135 funds tracked by Wall St. Rank hold CGEM as of Q2 2024.

  • Parkman Healthcare Partners reported no remaining Cullinan Oncology position as of Q2 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 178,396 Cullinan Oncology shares in Q2 2024, an estimated $3.04M.
  • Parkman Healthcare Partners first reported a position in Cullinan Oncology in Q4 2022 and held it in 6 quarters.
  • Parkman Healthcare Partners's Cullinan Oncology position peaked at $5.4M in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.